Predicting Early Chemotherapy Response with Technetium-99m Methoxyisobutylisonitrile SPECT/CT in Advanced Non-Small Cell Lung Cancer

[1]  F. Hoebers,et al.  99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome , 2008, Nuclear medicine communications.

[2]  F. Hoebers,et al.  99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Verheij,et al.  Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Z. Burak,et al.  Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer , 2006, Annals of nuclear medicine.

[5]  M. Salvatore,et al.  99mTc-MIBI in the evaluation of breast cancer biology , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  S. Ho,et al.  Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer. , 2003, Cancer letters.

[7]  U. Sanli,et al.  99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Ciarmiello,et al.  Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  A. Salan,et al.  99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  G. D'aiuto,et al.  Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  S. Sun,et al.  Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J C Reed,et al.  Apoptosis-regulating proteins as targets for drug discovery. , 2001, Trends in molecular medicine.

[13]  D. Hedley,et al.  Comparison of 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function , 2001, British Journal of Cancer.

[14]  A. Ciarmiello,et al.  Scintigraphic detection of multidrug resistance in cancer. , 2000, Cancer biotherapy & radiopharmaceuticals.

[15]  Y. Nishiyama,et al.  Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. , 2000, Clinical nuclear medicine.

[16]  C. Kao,et al.  Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  A. Ciarmiello,et al.  Clinical imaging of multidrug resistance in cancer. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[19]  M. Moore,et al.  99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. , 1999, Nuclear medicine communications.

[20]  T. Yen,et al.  Technetium‐99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma , 1998, Cancer.

[21]  S. Emri,et al.  Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  B. Beghé,et al.  Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. , 1997, Nuclear medicine communications.

[23]  J. Kouyoumdjian,et al.  Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression , 1996, European Journal of Nuclear Medicine.

[24]  U. Germann,et al.  P-glycoprotein--a mediator of multidrug resistance in tumour cells. , 1996, European journal of cancer.

[25]  H. Goldschmidt,et al.  Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas , 1995, European Journal of Nuclear Medicine.

[26]  J. Kronauge,et al.  Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. , 1990, Circulation.

[27]  J. Kronauge,et al.  Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  D. Berman,et al.  Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[30]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[31]  Y. Nishiyama,et al.  Comparative evaluation of Tc-99m MIBI and Tl-201 chloride SPECT in non-small-cell lung cancer mediastinal lymph node metastases. , 2000, Clinical nuclear medicine.

[32]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[33]  H. Bom,et al.  Technetium-99m-MIBI uptake in small cell lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  W T Bellamy,et al.  P-glycoproteins and multidrug resistance. , 1996, Annual review of pharmacology and toxicology.

[35]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.